Mar 28 |
Unicycive Therapeutics GAAP EPS of -$1.28, revenue of $0.7M
|
Mar 28 |
Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update
|
Mar 25 |
Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress
|
Mar 14 |
Unicycive rises 4% on $50M private placement
|
Mar 14 |
Unicycive Announces $50 Million Private Placement
|
Mar 13 |
Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference
|
Mar 7 |
Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)
|
Feb 14 |
Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting
|
Jan 24 |
Unicycive (UNCY) Up on Positive Hyperphosphatemia Study Update
|
Jan 23 |
Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones
|